TY - JOUR
T1 - Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice
AU - Polin, Lisa
AU - Valeriote, Frederick
AU - White, Kathryn
AU - Panchapor, Chiab
AU - Pugh, Susan
AU - Knight, Juiwanna
AU - LoRusso, Patricia
AU - Hussain, Maha
AU - Liversidge, Elaine
AU - Peltier, Nancy
AU - Golakoti, Trimurtulu
AU - Patterson, Gregory
AU - Moore, Richard
AU - Corbett, Thomas H.
N1 - Funding Information:
Supported by grants CA53001, CA46560, and CA12623 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.
PY - 1997
Y1 - 1997
N2 - Both the PC-3 and the TSU-PR1 prostate tumor models were found to be satisfactory for chemotherapeutic investigations in ICR-SCID mice. The 30 to 60 mg fragments implanted took in all mice (as judged by 100% takes in the controls of all experiments as well as the passage mice). The tumor volume doubling time was 4.0 days for PC-3 and 2.5 days for TSU-PR1. Nine agents were evaluated IV against early stage subcutaneous PC-3 tumors, with Nano-piposulfan being the only agent highly active (4.9 log kill). Three other agents were moderately active: Taxol (1.5 log kill), Cryptophycin-8 (1.6 log kill), Vinblastine (1.0 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and Cyclophosphamide. Ten agents were evaluated IV against early stage subcutaneous TSU-PR1 tumors. Three agents were highly active, producing > 6 log kill and cures: Taxol (5/5 cures), Cryptophycin-8 (5/5 cures), Vinblastine (2/4 cures). Two other agents were moderately active: Nano-piposulfan (1.2 log kill), and Cyclophosphamide (1.1 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and BCNU. In part, activity was determined by the ability of the SCID mice to tolerate meaningful dosages of the agents. Agents producing granulocyte toxicity (e.g., Adriamycin) were poorly tolerated and appeared less active than expected. Vinblastine, producing little or no granulocyte toxicity was very well tolerated and appeared to be more active than expected.
AB - Both the PC-3 and the TSU-PR1 prostate tumor models were found to be satisfactory for chemotherapeutic investigations in ICR-SCID mice. The 30 to 60 mg fragments implanted took in all mice (as judged by 100% takes in the controls of all experiments as well as the passage mice). The tumor volume doubling time was 4.0 days for PC-3 and 2.5 days for TSU-PR1. Nine agents were evaluated IV against early stage subcutaneous PC-3 tumors, with Nano-piposulfan being the only agent highly active (4.9 log kill). Three other agents were moderately active: Taxol (1.5 log kill), Cryptophycin-8 (1.6 log kill), Vinblastine (1.0 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and Cyclophosphamide. Ten agents were evaluated IV against early stage subcutaneous TSU-PR1 tumors. Three agents were highly active, producing > 6 log kill and cures: Taxol (5/5 cures), Cryptophycin-8 (5/5 cures), Vinblastine (2/4 cures). Two other agents were moderately active: Nano-piposulfan (1.2 log kill), and Cyclophosphamide (1.1 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and BCNU. In part, activity was determined by the ability of the SCID mice to tolerate meaningful dosages of the agents. Agents producing granulocyte toxicity (e.g., Adriamycin) were poorly tolerated and appeared less active than expected. Vinblastine, producing little or no granulocyte toxicity was very well tolerated and appeared to be more active than expected.
KW - Chemotherapy
KW - PC-3
KW - Preclinical
KW - Prostate tumors
KW - TSU-PR1
UR - http://www.scopus.com/inward/record.url?scp=8244245753&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8244245753&partnerID=8YFLogxK
U2 - 10.1023/A:1005856605726
DO - 10.1023/A:1005856605726
M3 - Article
C2 - 9220288
AN - SCOPUS:8244245753
VL - 15
SP - 99
EP - 108
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 2
ER -